Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07084129 · ClinicalTrials.gov registry record · Phase 1
Vancomycin and Acute Kidney Injury in Sepsis Treatment - Intervention
A Phase 1 study of Sepsis, sponsored by Children's Hospital of Philadelphia.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT07084129 is a Phase 1 study of Sepsis that is actively recruiting participants, run by Children's Hospital of Philadelphia. The registered enrollment target is 20 participants, below the 6,564-participant average among 90 other Sepsis trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07084129, a Phase 1 study of Sepsis, is actively recruiting participants, sponsored by Children's Hospital of Philadelphia.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to determine if vancomycin dosing in children with sepsis can be improved by using updated, personalized dosing models that account for new markers of an individual's kidney function. Vancomycin is prescribed based on the known information of how the body breaks this medicine down. Vancomycin may not be effective if blood levels of the medicine are too low. Vancomycin has potential side effects, including the possibility of injury to the kidney. These side effects usually happen when blood levels of vancomycin are too high. There are guidelines for the range of vancomycin blood levels doctors should target to treat an infection and lower the risk of side effects. Children with sepsis may metabolize vancomycin at different rates, faster or slower, than children who do not have sepsis. For these reasons, the current dosing strategy may lead to a higher risk of kidney injury or a risk of not adequately treating an infection in children with sepsis. The investigators' goal is to use new vancomycin dosing equations to improve the ability to select the right dose of vancomycin. The main questions this trial aims to answer are: 1. Is it feasible to use personalized models of vancomycin dosing in children with sepsis? 2. Will personalized models of vancomycin dosing achieve vancomycin blood levels in acceptable ranges?
Conditions Studied
Interventions
- OTHER personalized dosing adjustment of vancomycin
Study Locations (1)
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-04 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07084129
The ClinicalTrials.gov registry entry for NCT07084129 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 6,564-participant average among 90 other Sepsis trials with a reported enrollment target (100% lower). The listed sponsor is Children's Hospital of Philadelphia, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sepsis appearing as the primary indexed condition, and to 1 intervention - of which personalized dosing adjustment of vancomycin is the first listed.
NCT07084129 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07084129 about?
NCT07084129 is a clinical study titled "Vancomycin and Acute Kidney Injury in Sepsis Treatment - Intervention". The goal of this clinical trial is to determine if vancomycin dosing in children with sepsis can be improved by using updated, personalized dosing models that account for new markers of an individual's kidney function. Vancomycin is prescribed based on the known information of how the body breaks th...
What is the current status of trial NCT07084129?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2026-04. Estimated completion is 2026-12-31.
What conditions does trial NCT07084129 study?
This clinical trial studies the following conditions: Sepsis.
What interventions are being tested in trial NCT07084129?
The interventions under investigation include: personalized dosing adjustment of vancomycin (OTHER).
Who is sponsoring clinical trial NCT07084129?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07084129 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sepsis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety Study of Inhaled Carbon Monoxide to Treat Pneumonia and Sepsis-Induced Acute Respiratory Distress Syndrome (ARDS)
ACTIVE NOT RECRUITING · Phase 1
-
Imipenem-Relebactam Pharmacokinetics in Augmented Renal Clearance
COMPLETED · Phase 1
-
Phase I Study of Vasoactive Intestinal Peptide in Patients With Acute Respiratory Distress Syndrome and Sepsis
COMPLETED · Phase 1
-
Skin Cleansing With Chlorhexidine to Decrease Hospital Acquired Infections
COMPLETED · Phase 1
-
Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome
COMPLETED · Phase 1
-
The APS Phenotyping Study
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.